Back to top
more

Melinta Therapeutics, Inc. (MLNT)

(Delayed Data from NSDQ)

$4.62 USD

4.62
228,695

+0.38 (8.96%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.59 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Melinta Therapeutics, Inc. [MLNT]

Reports for Purchase

Showing records 1 - 20 ( 34 total )

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 1

12/31/2019

Company Report

Pages: 2

Clock Strikes Midnight For Shareholders

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 2

12/23/2019

Company Report

Pages: 4

Loan Defaults Appear Inevitable; Terminating Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 3

11/14/2019

Company Report

Pages: 6

3Q19 Recap: Default Looms; Strategic Options Appear Limited Following Major Write-Down

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 4

11/14/2019

Company Report

Pages: 2

Chapter 11 Filing

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 5

10/25/2019

Daily Note

Pages: 3

Failure to Launch Likely to Impact Shares Further; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 6

10/25/2019

Company Report

Pages: 2

CAP Approval Yields to Cash Crisis

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 7

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for MLNT

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 8

08/12/2019

Company Report

Pages: 2

No Relief in Sight

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 9

08/12/2019

Company Report

Pages: 7

Both Chairman and CEO Abruptly Resign; Downgrade to Neutral and Remove PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 10

07/18/2019

Company Report

Pages: 5

2Q Preannouncement Underwhelming in Light of Amended Debt Terms

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 11

07/03/2019

Company Report

Pages: 2

Covenants at Risk - Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 12

06/20/2019

Company Report

Pages: 10

Expecting Baxdela Approval for CABP by October 24 PDUFA; Affirm Buy, Adjust PT to $13

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 13

06/20/2019

Company Report

Pages: 2

That Escalated Quickly - Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 14

05/10/2019

Company Report

Pages: 2

Lowering to Sell on Covenant Concerns

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 15

05/10/2019

Company Report

Pages: 5

1Q19 Recap; We See Potential Upside in Baxdela for CABP and EU Approval for ABSSSI; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 16

03/25/2019

Company Report

Pages: 8

After Resetting the Bar, 2019 Looks to Be a Year of Must-Make Execution; Reduce PT to Split-Adjusted $45

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 17

03/15/2019

Company Report

Pages: 2

Q4 Update - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 18

02/04/2019

Daily Note

Pages: 3

Melinta Expands Commercial Team With New CCO and Confirms Financial Guidance; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 19

12/20/2018

Company Report

Pages: 2

Amended Lifeline - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 20

12/20/2018

Company Report

Pages: 5

Removing Uncertainty: New Credit Facility Extends Cash, as Interim CEO Becomes Permanent

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party
// eof